Your browser is no longer supported. Please, upgrade your browser.
Settings
KZR Kezar Life Sciences, Inc. daily Stock Chart
KZR [NASD]
Kezar Life Sciences, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own24.72% Shs Outstand21.01M Perf Week-13.47%
Market Cap171.44M Forward P/E- EPS next Y-2.35 Insider Trans- Shs Float14.39M Perf Month-58.49%
Income-25.90M PEG- EPS next Q-0.49 Inst Own52.10% Short Float8.04% Perf Quarter-55.53%
Sales- P/S- EPS this Y-385.50% Inst Trans5.66% Short Ratio10.80 Perf Half Y-64.04%
Book/sh5.36 P/B1.52 EPS next Y-15.20% ROA-21.80% Target Price23.67 Perf Year-
Cash/sh4.82 P/C1.69 EPS next 5Y- ROE-23.30% 52W Range7.79 - 36.33 Perf YTD-65.42%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.54% Beta-
Dividend %- Quick Ratio21.80 Sales past 5Y- Gross Margin- 52W Low4.75% ATR0.95
Employees24 Current Ratio21.80 Sales Q/Q- Oper. Margin- RSI (14)23.21 Volatility9.22% 8.19%
OptionableNo Debt/Eq0.00 EPS Q/Q-48.60% Profit Margin- Rel Volume1.07 Prev Close7.86
ShortableYes LT Debt/Eq0.00 EarningsMar 21 Payout- Avg Volume107.16K Price8.16
Recom- SMA20-25.54% SMA50-50.13% SMA200-59.87% Volume115,504 Change3.82%
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
Jun-14-19 08:47AM  The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga -8.97%
Jun-13-19 04:01PM  Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting GlobeNewswire
Jun-10-19 04:05PM  Kezar Life Sciences to Host Conference Call and Webcast at the EULAR 2019 Annual Meeting to Discuss Results of First in Patient Study with KZR-616 GlobeNewswire
May-29-19 07:38AM  The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation Benzinga
May-28-19 07:31PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Kezar Life Sciences, Inc. - KZR GlobeNewswire -41.39%
07:00AM  Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting GlobeNewswire
May-25-19 10:08AM  Did Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Buy Up More Shares? Simply Wall St.
May-20-19 04:53PM  Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea American City Business Journals
May-14-19 04:05PM  Kezar Life Sciences Announces Presentations at Two Upcoming Investor Conferences GlobeNewswire
May-09-19 08:56PM  Here is What Hedge Funds Think About Kezar Life Sciences, Inc. (KZR) Insider Monkey
May-07-19 04:05PM  Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-03-19 08:00AM  Kezar Life Sciences to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
Mar-28-19 04:05PM  Kezar Life Sciences Announces Presentations at Upcoming Scientific Conferences GlobeNewswire
Mar-26-19 08:00AM  Kezar Life Sciences Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-06-19 04:05PM  Kezar Life Sciences Announces Initiation of Clinical Study to Test a New Drug Product Formulation of KZR-616 GlobeNewswire
Mar-05-19 08:00AM  Kezar Life Sciences to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Mar-04-19 05:00PM  Kezar Life Sciences Strengthens Management Team, Appoints Celia Economides as Senior Vice President, Strategy and External Affairs GlobeNewswire
Dec-20-18 01:05PM  These 4 Biotech Stocks are Picking Up Speed ACCESSWIRE +10.25%
Dec-05-18 08:00AM  Kezar Life Sciences to Present at The BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals -5.90%
Nov-08-18 08:00AM  Kezar Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-07-18 08:00AM  Kezar Life Sciences to Present at Jefferies 2018 London Healthcare Conference GlobeNewswire
Aug-29-18 08:00AM  Kezar Life Sciences to Present at 2018 Wells Fargo Healthcare Conference GlobeNewswire
Aug-09-18 04:05PM  Kezar Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-17-18 10:00AM  Former Pappas Portfolio Company CEO Retracts Anonymous Allegations PR Newswire
Jun-29-18 02:39PM  Here's how 14 Bay Area IPOs did in the strongest first half in 4 years American City Business Journals
Jun-28-18 09:07AM  Pair of upsized Bay Area biotech IPOs head in opposite directions after raising $335M American City Business Journals
Jun-25-18 04:05PM  Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares PR Newswire
02:37PM  The Funded: More biotech IPOs highlight Bay Area venture news this week, along with a new Jay Z VC fund American City Business Journals
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 08:05PM  Kezar Life Sciences Announces Pricing of Initial Public Offering PR Newswire
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. The company was founded in 2015 and is headquartered in South San Francisco, California.